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The clinical course of breast cancer is more of a chronic nature, as compared to other, highly curable malignancies, such as
testicular cancer, acute leukemia and Hodgkin’s disease. Therefore, ﬁve-year and ten-year relapse-free survival is not equivalent to
cure. Patients with operable breast cancer can be cured with combined modality therapies. The probability of cure is inversely
proportional to initial stage. The hazard rate of relapse is highest during the ﬁrst three to ﬁve years and decreases gradually there-
after. Survival curves for operable breast cancer start to parallel the survival of the general population 15 to 25 years after diag-
nosis. Between a quarter to a third of patients with locally advanced and/or inﬂammatory breast cancer are curable with combined
modality strategies and a small fraction of highly selected patients with overt metastatic breast cancer have lengthy complete
remissions after chemotherapy or combined modality therapy. In recent years proof of principle was obtained for chemoprevention
with selective estrogen receptor modulators in several multicenter trials. Additional studies are ongoing to determine the optimal
preventive intervention.
# 2003 Elsevier Ltd. All rights reserved.Whether you believe you can, or whether you
believe you can’t, you’re absolutely right.
Henry Ford1. Introduction
Breast cancer remains the most common malignancy
in women in the USA and Western Europe [1,2]. Its
incidence is increasing in the rest of the world, where it
is usually second in importance after cervical uterine
cancer. It is calculated that approximately 800 000 to 1
million new cases of breast cancer will be diagnosed in
the world this year [2].
Breast cancer represents the second most common
cause of cancer mortality in women in the industrialized
western world, second only to lung cancer [1,2]. Over
the past decade, national statistics from the USA, the
UK, Italy, Switzerland and other countries show a sig-
niﬁcant gradual decrease in breast cancer mortality; this
trend has persisted for almost 10 years now [2–5]. Whe-
ther the signiﬁcant reduction in breast cancer mortality
is due to earlier diagnosis secondary to systematic use of
screening mammography or the improvement in com-bined modality management of all stages of breast can-
cer is diﬃcult to determine [6–9]. It is likely that both
have contributed to this trend.2. The concept of curability
Whether breast cancer is curable or not has been
hotly debated for many years [10–15]. Therefore, before
we review the evidence, it is critical to deﬁne our terms.
Clearly, breast cancer is often an indolent disease.
Therefore, arbitrary deﬁnitions of cure (such as 5-year
disease-free survival) are irrelevant for all but a small
minority of elderly patients with limited life expectancy
[13,16–18]. Other malignancies, especially those con-
sidered to run an acute course, are more appropriately
considered cured if no relapses occur 2 or 5 years fol-
lowing completion of curative treatment. In those
malignancies, late relapses occur infrequently, so
patients who reach the landmark date are very likely to
be cured.
Numerous publications have demonstrated that
breast cancer does not belong in this category. Long-
term follow-up of untreated breast cancer clearly shows
that, essentially, all patients will die of the disease [19–21].
However, it must be realised that comorbid conditions
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with metastatic breast cancer [22–26]. Comorbid condi-
tions increase in frequency with age, so older patients
with breast cancer have a higher probability of dying of
causes diﬀerent from breast cancer. On the basis of
these observations, the concept of personal cure arose.
A patient with breast cancer achieves a personal cure if,
following completion of curative treatment she even-
tually dies from a diﬀerent cause (e.g. cardiovascular
disease, chronic obstructive lung disease, stroke, etc.)
before a relapse from breast cancer can be documented.
Certainly, for individual patients, this is a perfectly
satisfactory deﬁnition of cure. However, from the bio-
logical and statistical perspective, this deﬁnition is still
inadequate and provides insuﬃcient support for the
worth of a speciﬁc treatment.
Statistical cure has been deﬁned on the basis of
population survival ﬁgures [13,17,18]. Thus, it is con-
sidered that a group of patients with breast cancer has
achieved cure in statistical terms if its survival curve
becomes parallel to the survival curve of the general
population. For additional precision, these comparisons
are made on age-matched populations.
The mortality rate of breast cancer increases with
clinical and pathological stage [27,28]. In fact, corre-
lations of clinical characteristics with mortality after
treatment deﬁned clinical stages in the ﬁrst place [29,30].
Hazard rates of mortality show that there is an initial
peak of several years in hazard rates, followed by a
gradual decline over subsequent years [15,17]. The
initial peak is higher and narrower for more advanced
stages (stages III and IV); most relapses and deaths
occur within the ﬁrst 3–5 years in these groups. In con-
trast, patients diagnosed with stages I and II evidence a
lower peak that tends to occur later. Thus, the survival
curves of patients with more advanced or higher-risk
breast cancer start to parallel the survival curves of the
general population earlier than the survival curves of the
earlier breast cancers. Stated in a diﬀerent way, higher-
risk breast cancer groups achieve statistical cure earlier
(10–15 years after diagnosis) than lower-risk groups
(20–25 years after diagnosis). Because such lengthy
follow-up is necessary for complete evaluation of treat-
ment results, some have stated that breast cancer is, in
essence, incurable. This argument states that, if follow-
up is long enough, relapses will occur. The systematic
application of combined modality therapies and mam-
mographic screening has shown this position to be
mistaken [31]. Clearly, mammographically diagnosed
early breast cancer (stages 0 and I) is associated with
excellent survival rates, exceeding 90% at 20 years
following surgical resection alone or breast conserving
therapies; as shown below, 25 years after diagnosis,
the survival curves of patients with stages II, III and
even IV breast cancer suggest relapse-free survival
plateaux that parallel the survival curves of the general
population [13].3. Curative interventions
The eﬃcacy of all anticancer treatments is inversely
proportional to the stage of disease. Thus, patients with
stage I breast cancer have higher 5-, 10-, 20- and 30-year
survival rates than patients with stage II breast cancer
[13]. Each group with more advanced stage has lower
survival rates than the group with earlier stage at all
points of follow-up. This is true whether treatment is
surgery only, surgery with radiotherapy, or combined
modality therapy that incorporates surgery, chemo-
therapy, endocrine therapy and radiotherapy [7–
9,13,32]. There is extensive documentation of these
statements with follow-ups of 5 and 10 years. The Early
Breast Cancer Trialists Collaborative Group has devel-
oped prospective databases that now reach 15 years of
follow-up; it is hoped that such prospective data collec-
tion will continue to enable us to address the issues of
long-term curability with the highest levels of evidence.
In addition, a few, mostly single-institution databases
provide additional, long-term information.4. The curability of early breast cancer
Perhaps the best source for this information is derived
from long-term, prospective follow-up of the clinical
trials of screening mammography [31]. With follow-up
now exceeding 20 years, the Two County Trial reports
very high survival rates, in the range of 96–98%. Simi-
larly, patients with T1a+b N0 primary breast cancers
diagnosed and followed as part of the same study had a
20-year survival that exceeded 85%. Quiet and collea-
gues reported for this same group of patients a 40-year
disease-speciﬁc survival rate of 80% or more [33].
Clearly, in both Stage 0 and Stage I, patients die of
multiple other causes, but breast cancer is a cause of
death for only a minority of patients. Personal cure is
achieved for the great majority, and statistical cure is
accomplished after 20 years or so.5. The curability of lymph node-positive operable
breast cancer
Over the past three decades, more than 200 pro-
spective randomised trials have been completed to
determine the role and eﬃcacy of adjuvant chemo-
therapy, endocrine therapy and radiotherapy [7–9].
Most patients included in such trials had lymph node-
positive breast cancer. Most published trials have fol-
low-up ranging from 5 to 10 years, with a handful pro-
viding follow-ups exceeding 20 years. The world
overview of randomised trials, performed and updated
every 5 years since 1985, pools individual patient data and
provides answers to clinically relevant questions based onG.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34 25
thousands of patients. On the basis of large, individual
randomised clinical trials and on the basis of the overview,
we know that the eﬀects of systemic adjuvant therapy are
long term, and that these beneﬁcial eﬀects now exceed 15
years without any indication that the magnitude of the
eﬀects diminishes (2000 World Overview, unpublished
results). This is a remarkable observation, since treatment
in most adjuvant chemotherapy trials was administered
for 1 year or less, and for adjuvant tamoxifen, 5 years or
less. Therefore, our systemic interventions produce
long-term and apparently irreversible changes in the
clinical course of primary breast cancer. Since the fol-
low-up of a very large number of patients included in
these trials is now reaching or exceeding the time period
when the survival of breast cancer patients starts to
parallel that of the general population, it is increasingly
likely that the reduction in odds of recurrence and death
is equivalent to an increase in cure rate. Single-institu-
tion reports of the results of combined-modality treat-
ment of patients with node-positive or stage III disease
show that even for the highest risk category of patients
(i.e. those with more than 10 positive lymph nodes) 20–
40% of patients remain disease-free 15–20 years after
diagnosis [13,34–37].6. Locally advanced and inﬂammatory breast cancer
Other reports have documented that patients with
Stage IIIB disease can be rendered disease-free with
combined modality therapy and about one-third of
them remain disease-free more than 20 years later
[35,38–40] (Table 1). This is particularly dramatic in the
case of inﬂammatory breast cancer, previously con-
sidered the most aggressive and lethal form of breast
cancer. Before the introduction of chemotherapy into
the management of this type of breast cancer, more than
90% of patients treated with surgery and/or radio-
therapy developed metastases within the ﬁrst 24
months, and the 5-year survival rate was consistently
under 5% [41,42]. In contrast, these same patients trea-
ted with combined modality treatments that include
neoadjuvant anthracycline-containing chemotherapy
now routinely achieve 5-year survival rates that exceed
40%, and almost one-third of them remain relapse-free
20 years after diagnosis [38,43–46]. Since the hazard rateassociated with inﬂammatory breast cancer shows a
sharp peak within the ﬁrst 2 years and a rapid reduction
in risk in subsequent years, it is highly likely that the
great majority of patients alive 20 years after diagnosis
are cured. Another group of patients that deserves
comment is that with supraclavicular lymph node
involvement at presentation. In the current AJCC/
UICC clinical staging system, these patients are con-
sidered to have overt distant metastases and, therefore,
are considered incurable. However, our experience with
this group of patients treated with combined modality
therapy indicates that the great majority can be ren-
dered free of active disease, and that about one-third of
them remain progression-free (disease-free) 5 and 10
years after completion of all therapy [39] (Fig. 1). This
experience would also indicate that this group of
patients does not belong in the incurable category of the
staging classiﬁcation, and should be approached
aggressively, with curative intent.7. Metastatic breast cancer
It is generally believed that metastatic breast cancer is
incurable with currently available treatment modalities
[47,48]. In fact, and contrary to the experience reported
from metastatic colorectal cancer or soft-tissue and
osteogenic sarcoma, it is generally believed that surgical
resection of metastatic breast cancer is a futile exercise
and does not alter the natural history of the disease.
However, there are a few reports of surgical resection of
pulmonary metastases followed by lengthy relapse-free
periods, and anecdotal cases of successful resection of
liver, soft-tissue and brain metastases have been
observed [49–56]. At the M. D. Anderson Cancer Cen-
ter, we have approached patients with a single meta-
static lesion with combined modality therapy and
curative intent since 1974 [56–59]. Our strategy includes
surgical resection (which automatically provides histo-
logical conﬁrmation of metastases), radiotherapy and
systemic adjuvant chemotherapy and, when appro-
priate, endocrine therapy. Three consecutive, pro-
spective clinical trials included 321 patients, including
62 historical controls (Fig. 2). While we have attempted
to perform a randomised trial to assess the value
of adjuvant chemotherapy in this strategy, we were
unsuccessful in completing the targeted accrual. We
understand that several other groups have also failed in
their attempt to complete a randomised trial of adjuvant
chemotherapy in this setting. We have identiﬁed a
historical control group of patients with solitary
metastases treated at our institution between 1967 and
1976 with surgical resection with or without radio-
therapy, but without systemic treatment [56,58]. While
many of the patients treated with our combined mod-
ality approach presented with chest-wall recurrence orTable 1
Five-year survival rates of patients with inﬂammatory breast cancer
according to treatmentTreatment No. of
patientsPercent
aliveSurgery only 398 2
Radiotherapy 334 3
Both 142 5
Chemotherapy+local treatment(s) 708 4726 G.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34
distant soft-tissue metastases, up to 25% had bone or
visceral metastases (lungs, liver, or brain). With a med-
ian follow-up of 13 years and a maximal follow-up
approaching 27 years, the 15- and 20-year relapse-free
survival rates for this group of patients are 30 and 25%,
respectively. There have been only two second recur-
rences after 15 years, suggesting that the hazard rate
drops substantially after the initial decade of follow-up.
In contrast, the 15- and 20-year relapse-free survival
rates for the historical control patients were 3 and 3%,
respectively, indicating that in the absence of systemic
therapy, additional metastases or recurrences occur in
practically all patients once an initial recurrence or
metastasis has been detected.
A second group of patients with metastases is also
relevant to the discussion of cure. Between 1974 and
1982, we treated 1581 patients with clinical evidence of
metastatic breast cancer with ﬁrst-line, anthracycline-
containing chemotherapy (FAC, and related regimens)
[60–62]. All these patients were treated in prospective
clinical trials with anthracycline-based ﬁrst-line chemo-
therapy regimens. Their pretreatment evaluation was
similar across trials, and the deﬁnitions of response fol-
lowed in the assessment of eﬃcacy were also similar.
Since the outcome of the various treatments used in
these trials was similar in all trials, the results werepooled for an analysis of prognostic factors. Updates of
this same database with median follow-up times of 15 and
20 years demonstrated that a small percentage of patients
(3%) remained alive and disease-free in the absence
of maintenance therapy [63] (Fig. 3). Further analysis
indicated that all long-term disease-free survivors had
achieved a clinical complete remission with ﬁrst-line
therapy. Their characteristics included younger age,
excellent performance status and limited amount of
metastatic disease. This latter characteristic makes this
group similar to patients included in the Stage IV NED
category.
So where do we draw the line in terms of curability?
While quantitatively diﬀerent, some patients in Stages 0,
I, II, III and IV breast cancer can achieve a very long
period of disease-free survival with combined modality
therapy. Whether the percentage is 1 or 99%, the prac-
tical implications are the same: if there is a possibility of
cure (however remote), initial treatment should have
curative and not only palliative intent. In fact, whether
a 20-year long disease-free survival represents a cure or
not, it is a very substantial therapeutic achievement that
for many patients represents ‘personal’ cure.
The assumption that cure of breast cancer is not fea-
sible, except for the very early stages leads to a circular
argument: patients considered ‘incurable’ are oﬀeredFig. 1. Disease-free and overall survival of 178 patients with inﬂammatory breast cancer treated with neoadjuvant chemotherapy, radiotherapy with
or without mastectomy at the University of Texas M. D. Anderson Cancer Center (from Ref. [38], reprinted with permission from BC Decker Inc.).G.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34 27
only palliative treatments, thus missing any possibility
to achieve a cure. While this is often justiﬁed by stating
that, in the absence of cure, oﬀering the least toxic
treatment is the most ethical treatment policy, it is the
wrong approach.
Over the past decade, several new and eﬀective anti-
cancer agents have been added to our treatment arma-
mentarium [64–66]. Several of these (the taxanes,
capecitabine, trastuzumab, the third-generation aroma-
tase inhibitors) have been shown to prolong survival of
patients with metastatic breast cancer in the context of
randomised trials. These agents must be incorporated
rapidly into ﬁrst-line therapy of patients with high-risk
primary or metastatic breast cancer. We must do similarly
with the host of new agents under development today,
once their eﬃcacy is determined, and their contribution
into the overall management of breast cancer is deﬁned.
Only such therapeutic attitude will provide the maximum
possibility of cure for patients with breast cancer.8. Preventive strategies
The past decade witnessed the emergence of several
cancer-prevention strategies, with preliminary doc-
umentation of eﬀectiveness in reducing risk of develop-ing breast cancer. I will brieﬂy review and summarise
this experience, focusing mostly on reports of immediate
clinical relevance. It is intuitive that the best cure is
prevention, and this summary should complement the
former segment about curative strategies for various
stages of breast cancer.
A combination of environmental factors (e.g. expo-
sure to carcinogens, lifestyle and hormonal factors) and
genetic factors plays a role in the development of breast
cancer and aﬀects both incidence and mortality rates.
Increased understanding of the mechanisms of malig-
nant transformation, as well as the identiﬁcation of
potential markers of increased risk of developing breast
cancer, facilitated the appearance of chemoprevention
as a potentially useful early intervention. The quantiﬁ-
cation of risk of developing cancer is usually estimated
from epidemiologic models, which consider a variety
of risk factors and project a cumulative risk for the
development of disease over a ﬁnite period of time
[67–69]. Among the various models proposed, the one
developed by Gail and colleagues is probably the most
widely accepted [70]. Proposed in 1989 and subse-
quently modiﬁed, this model attempted to deﬁne the
contributions of multiple risk factors combined in a
multivariate logistic regression model. The variables
identiﬁed were patient’s age, number of ﬁrst-degreeFig. 2. Disease-free survival of patients with stage IV-NED breast cancer according to study group (from Ref. [56], reprinted with permission from
Blackwells Publishing Ltd.).28 G.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34
relatives with breast cancer, nulliparity or age at ﬁrst live
birth, number of breast biopsies, presence or absence of
atypical hyperplasia, and age at menarche. In particular,
women with a strong family history of breast cancer or
of breast and ovarian cancers have a lifetime risk of
developing breast cancer 25% or greater. The ‘Gail
model’ is the most widely used and validated to date, but
it has several weaknesses. The model does not clearly
quantify the risk for women with a hereditary predispo-
sition (e.g. a BRCA1 or BRCA2 mutation) and, although
the personal menstrual and reproductive histories are
included, other factors, such as the use of hormonal
replacement therapy, are not considered. It is hoped
that the inclusion of other signiﬁcant risk factors will
allow future models to more precisely deﬁne personal risk.
Risk-reduction attempts have followed diverse strate-
gies: chemoprevention, surgical ablation of the breast or
the ovaries, and dietary and behavioural modiﬁcation.9. Chemopreventive agents for breast cancer
Chemoprevention is the inhibition or reversal of car-
cinogenesis before the onset of overt malignancy. Thisintervention employs chemical agents that have demon-
strated eﬃcacy and safety in preclinical and animal
models, with the hope that these agents will be safe and
eﬀective in prospective clinical trials.
9.1. Anti-oestrogens or selective oestrogen receptor mod-
ulators (SERMs)
Tamoxifen is a non-steroidal triphenylethylene deri-
vative that is generally classiﬁed as an anti-oestrogen
with partial oestrogen-agonist activity in some tissues.
Results from chemopreventive and adjuvant trials sug-
gest that treatment with tamoxifen is associated with an
increase in bone-mineral density and a decrease in
serum cholesterol levels, especially in postmenopausal
women [74,75]. The use of adjuvant tamoxifen following
primary surgery for oestrogen-sensitive early breast
cancer has been associated with prolonged disease-free
survival and a 20–30% reduction in mortality rate [76].
Tamoxifen also produces a signiﬁcant reduction in the
incidence of second primary tumours in the con-
tralateral breast [71–73].
An overview analysis of the major randomised
trials of adjuvant tamoxifen among nearly 30 000Fig. 3. Long-term follow-up of 1581 chemotherapy-naı¨ve patients with metastatic breast cancer treated with anthracycline-containing ﬁrst-line
chemotherapy regimens. Progression-free survival (from Ref. [63], reprinted with permission of the American Society of Clinical Oncology).G.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34 29
women with early breast cancer demonstrated a 47%
reduction in the incidence of contralateral breast
cancer with 5 years of adjuvant tamoxifen [76].
Tamoxifen treatment appeared to be associated with
a signiﬁcant increase in the incidence of endometrial
cancer [76].
Since 1986, four studies explored the hypothesis that
long-term tamoxifen treatment reduced the risk of
developing breast cancer in women at high risk for this
disease [77–82]. In aggregate, these four studies
demonstrated that tamoxifen signiﬁcantly reduced the
risk of developing breast cancer. This eﬀect was
accompanied by an increase in the incidence of throm-
boembolic complications and endometrial cancer [77].
These eﬀects were more prominent in women over the
age of 50 years, especially those with an intact uterus.
No survival beneﬁt has been reported to date from these
four trials [80]. The beneﬁt/risk ratio is clearly higher for
high-risk women, those who have a greater than 1.7%
5-year probability of developing breast cancer.
In the past decade, reports of signiﬁcant side-eﬀects
associated with the prolonged use of tamoxifen have
stimulated research directed toward the development of
other selective oestrogen receptor modulators. Among
the various products investigated, raloxifene has
demonstrated antitumour activity and a favourable
toxicity proﬁle [83–85].
Clinical trials are underway to establish the role of
raloxifene in preventing osteoporosis in postmenopausal
women, and preliminary results from randomised clin-
ical trials have recently become available. The Multiple
Outcomes of Raloxifene Evaluation (MORE) trial was
speciﬁcally designed to reduce the risk of fractures in
postmenopausal women receiving raloxifene; a mark-
edly reduced risk of newly diagnosed breast cancer was
demonstrated with raloxifene compared to placebo
(0.21% versus 0.82%) [86,87]. Treatment with ralox-
ifene was associated with a 58% reduction in the risk of
developing primary breast cancer [87]. These results
have stimulated the design of a second major breast
cancer prevention trial, the Study of Tamoxifen And
Raloxifene (STAR or P-2), comparing the toxicity, risks
and beneﬁts of raloxifene with those of tamoxifen.
Women enrolled in the study are to be randomly
assigned to receive either 20 mg of tamoxifen or 60 mg
of raloxifene for 5 years, with follow-up planned for 2
additional years.
9.2. Retinoids
Retinoids are a family of natural and synthetic com-
pounds structurally related to vitamin A. They modulate
biological functions, such as proliferation, diﬀerentiation,
and the induction of apoptosis [73,88–90]. Retinoids
function via two types of nuclear receptors, the retinoid
alpha-receptors (RARs) and the retinoid X receptors(RXRs), and their action is modulated by cellular reti-
nol binding proteins (CRBP) [91]. All benign and
malignant breast tissues expressed RAR a, b, g and
CRBP-1 mRNAs [92].
Preclinical data have demonstrated that carcinogen-
induced mammary carcinomas are sensitive to the anti-
proliferative eﬀects of retinoids [73,93,94]. Fenretinide,
the ﬁrst retinoid to be tested in clinical trials, is well
tolerated at a daily dose of 200 mg with a 3-day monthly
drug holiday [95,96].
An Italian prospective randomised trial designed to
evaluate the role of fenretinide in reducing the incidence
of contralateral breast cancer began in March 1987 and
included 2972 women ranging in age from 30 to 70
years, with a history of T1-2, N0 breast cancer [95,96].
Preliminary data suggested that fenretinide reduced the
incidence of ovarian carcinomas [96]. Though safer than
other retinoids in experimental models, fenretinide pro-
duced visual (dark adaptation) and ophthalmological
complaints (ocular dryness, lacrimation, conjunctivitis,
and photophobia) in 20 and 8%, respectively, of women
at 5 years [97].10. Dietary interventions
Epidemiological studies showing large international
diﬀerences in the incidence of breast cancer have sug-
gested a relationship between diet and the development
of cancer. The age-adjusted incidence of breast cancer
varies from 22 per 100 000 individuals in Japan to 68 per
100 000 individuals in The Netherlands [98]. The ratio of
breast cancer mortality in the United States to that of
Japan is 3:1 for premenopausal women and 8:1 for
postmenopausal women [99]. These disparities may be
related to diﬀerences in dietary fat and calories as well
as the higher use of soy products by Asian women [100–
102].
The Canadian Diet and Breast Cancer Prevention
Study Group conducted a multicentre randomised
trial involving women with areas of abnormal breast
densities detected on mammography. The study
showed a signiﬁcant reduction in the number of
radiographic abnormalities after 2 years of a low fat
diet (i.e. less than 15% of calories from fat) [103]. The
Women’s Intervention Nutrition Study and the
Women’s Healthy Eating and Living Study are cur-
rently evaluating the beneﬁts of limiting fat intake to
15% of calories for women with postmenopausal
breast cancer [104]).
Alcohol consumption has also being extensively
investigated as a possible risk factor for breast cancer
[105]. While most studies have documented that high
alcohol intake is associated with a signiﬁcantly increased
incidence of breast cancer, no deﬁnitive evidence exists
on the favourable eﬀect of reducing alcohol intake.30 G.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34
11. Surgical prophylaxis and modulation of risk
11.1. Prophylactic mastectomy
It seems intuitive that mastectomy would be an eﬀec-
tive means of preventing breast cancer. However, data
from both laboratory studies and animal models and
clinical trials have conﬁrmed that this is not always the
case [106–108]. Studies have demonstrated that even
total mastectomy (deﬁned as removal of the entire
breast, including the nipple–areolar complex, but spar-
ing the axillary contents) is frequently incomplete;
microscopic amounts of breast tissue may remain in the
skin ﬂaps, attached to the pectoralis fascia, and extend-
ing into the axilla [107].
The clinical signiﬁcance of retained breast tissue in the
setting of prophylactic mastectomy for humans is not
yet deﬁned. Data on prophylactic bilateral mastectomy
in humans are limited. The studies by Pennisi and
Capozzi [109] and Woods and Meland [110] each
involved at least 1500 women who underwent sub-
cutaneous mastectomies and, in both studies, the post-
surgical incidence of breast carcinoma was less than 1%
[109,110]. However, both studies have been criticised for
their limited applicability to high-risk women, because
the women in these series would today be considered to
be at only low or intermediate risk for breast cancer.
Detailed follow-up information is also lacking in these
large series.
It remains to be determined whether a prophylactic
total mastectomy is clearly indicated for women with a
high-risk for developing breast cancer. Women with
BRCA1 mutations, who may have a cumulative breast
cancer risk of 40–85%, would be the obvious candidates
[111,112].
Schrag and colleauges [113] developed a statistical
model to calculate the beneﬁt of prophylactic mas-
tectomy for individuals with a BRCA1 or BRCA2 muta-
tion. Using a risk-reduction estimate of 85% associated
with prophylactic mastectomy, this study determined
that a 30-year-old BRCA1 mutation carrier would gain
from 2.9 to 5.3 years of life expectancy following pre-
ventive surgery. Lynch and colleagues [114] reported on
the results of a series of women who had undergone
extensive genetic counseling and subsequently tested
positive for BRCA1 gene mutations. Only 35% of these
patients said they would consider undergoing prophy-
lactic mastectomy. This ﬁnding underscores the com-
plexity of identifying high-risk women who will beneﬁt
psychologically as well as clinically from preventive
surgery.
Hartmann and colleagues recently reported the results
[115] of a retrospective analysis performed on 639
women with moderate or high risk for breast cancer
(based on family history) who had undergone bilateral
prophylactic subcutaneous mastectomy between 1960and 1993. The breast-cancer incidence in these women
was compared with the number of expected cases based
on the Gail model, and to the number of cases that
occurred among the patients’ female siblings who had
not undergone prophylactic surgery; these estimations
revealed an approximately 90% reduction in breast
cancer risk associated with prophylactic mastectomy.
The Society of Surgical Oncology has delineated
categories of patients for whom prophylactic mas-
tectomy may reasonably be considered on the basis of
clinical features (and not including genetic testing
results) [116]. For women with no history of breast
cancer, the indications include atypical hyperplasia; a
family history of premenopausal bilateral breast cancer;
and dense, nodular breasts associated with atypical
hyperplasia. For women with a known unilateral breast
cancer, the indications for considering contralateral
prophylactic mastectomy include diﬀuse microcalciﬁca-
tions; lobular carcinoma in situ; a large, diﬃcult-to-
evaluate breast; a history of lobular carcinoma in situ;
and a family history of early-onset breast cancer.
11.2. Prophylactic ovarian ablation
Several retrospective, matched control analyses of the
eﬀects of ovarian ablation on the incidence of breast
cancer in high-risk women have been published over the
past few years [117–119]. In general terms, bilateral
ovarian ablation reduced the incidence of breast and
ovarian cancer in high-risk women, including those with
known BRCA1 or BRCA2 mutations. Whether chemical
ovarian suppression, by using Gonadotropin analogues,
would have the same results, remains to be determined.12. Conclusions
The encouraging results from tamoxifen studies, and
the ongoing clinical trials of raloxifene, retinoids,
aromatase inhibitors and other approaches suggest
that physicians and scientists are increasingly cogni-
zant of chemoprevention and its potentially enormous
socioeconomic implications. Breast-cancer chemo-
prevention is a rapidly evolving ﬁeld that has the
potential to signiﬁcantly reduce the incidence of breast
cancer.
In the past decade, our increasing understanding of
the roles that genetic, hormonal, dietary and environ-
mental factors play in the development of breast cancer
has greatly improved our ability to determine individual
risk of breast cancer and to properly select high-risk
groups for interventional studies. Prospective clinical
trials of chemoprevention strategies should be limited to
high-risk populations identiﬁed on the basis of a com-
bination of epidemiological, histopathological and bio-
logical data. Ideally, these studies should use surrogateG.N. Hortobagyi / EJC Supplements Vol 1 No. 1 (2003) 24–34 31
endpoint biomarkers to evaluate the eﬃcacy of drug
interventions. This approach will contribute greatly to
reducing the size of patient populations under study,
eventually reducing the costs related to these investiga-
tions and helping to clarify the biology of each drug’s
mechanisms of action.
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